Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

283
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
283
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

467
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
467
Analgesia and Pain Management01:25

Analgesia and Pain Management

584
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
584
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

451
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
451
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

749
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
749

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The imaginary divide between mental and "physical" health: Dismantling dualism and reductionism to address a monumental mistake in medicine.

JCPP advances·2026
Same author

Association between initial benzodiazepine prescribing patterns and time to benzodiazepine discontinuation: A population-based retrospective cohort study.

PLoS medicine·2026
Same author

Transcranial Magnetic Stimulation for Bipolar Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Stimulation magnétique transcrânienne dans les cas de dépression bipolaire : une revue systématique et une méta-analyse d'essais contrôlés à répartition aléatoire.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026
Same author

The human microplastic burden and brain health: From measurement to pathophysiology and removal.

Brain health : lifelong brain resilience and longevity·2026
Same author

Eating disorder-related electrolyte abnormalities and adverse outcomes: A systematic review and meta-analysis.

PloS one·2026
Same author

One-Year Mortality Among Opioid Overdose Survivors.

JAMA·2026

Related Experiment Video

Updated: Jun 26, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.2K

High-Dose Buprenorphine Initiation: A Scoping Review.

Stanley Wong1, Nicholas Fabiano, Declan Webber

  • 1From the Department of Psychiatry, University of Toronto, Toronto, Canada (SW, RAK); Centre for Addiction and Mental Health, Toronto, Canada (RAK); Department of Psychiatry, University of Ottawa, Ottawa, Canada (NF); and Department of Family and Community Medicine, University of Toronto, Toronto, Canada (DC).

Journal of Addiction Medicine
|May 17, 2024
PubMed
Summary

High-dose buprenorphine initiation, exceeding 12 mg, shows no reported overdose or respiratory depression cases. However, limited data necessitates further research into its safety and effectiveness.

More Related Videos

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

7.5K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

338

Related Experiment Videos

Last Updated: Jun 26, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.2K
Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

7.5K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

338

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Clinical Research

Background:

  • High-dose buprenorphine initiation (>12 mg) is an emerging strategy for opioid use disorder treatment.
  • Understanding the safety and efficacy of this approach is crucial for clinical practice.

Purpose of the Study:

  • To review and synthesize existing literature on high-dose buprenorphine initiation.
  • To identify reported outcomes, adverse events, and limitations in current research.

Main Methods:

  • A comprehensive scoping review of multiple databases (MEDLINE, Embase, PsycINFO, Cochrane Central) was performed.
  • Included studies published in English before February 13, 2023, encompassing RCTs, cohort studies, and case reports.

Main Results:

  • Fifteen studies involving 580 high-dose buprenorphine initiations were analyzed across various settings.
  • No fatal or nonfatal overdose or respiratory depression events were reported.
  • Common side effects included nausea/vomiting and precipitated withdrawal; serious events were rare (e.g., hypotension).

Conclusions:

  • High-dose buprenorphine initiation appears safe regarding overdose and respiratory depression based on current literature.
  • Limitations include inconsistent adverse event reporting, limited follow-up, and lack of comparative data.
  • Further prospective studies are required to fully assess the safety and effectiveness of high-dose buprenorphine initiation.